Multi-stakeholder groups from government, academia, the medical and scientific community, the private sector, and patient organizations gathered in a forum to reignite discussions aimed at transforming the Philippines into a leading center for clinical trials in the ASEAN region.
University of the Philippines – National Institutes of Health (UP-NIH), Pharmaceutical and Health Association of the Philippines (PHAP), Department of Science and Technology – Philippine Council for Health Research (DOST-PCHRD), Department of Commerce – Board of Investment (DTI-BOI) and the Clinical Research Professionals of the Philippines (PCRP) led a forum on “The Philippines as a Center of Excellence in Clinical Trials: let’s make it happen” at the UP BGC Auditorium.
“Achieving the goal of making the Philippines the center of excellence for clinical trials in the region will involve bringing all stakeholders together, starting with a common understanding of their suitability and economic cost and clarifying the roles of stakeholders in achieving this. We are pleased to host this forum to demonstrate our commitment to achieving this transformation,” said UP-NIH Executive Director Eva Maria Cutiongco-Dela Paz, M. D.
Efforts to propel the Philippines as a center of excellence in clinical trials align with one of the goals of the Department of Health: Philippine Pharmaceutical Policy (PMP), which seeks to “build and design a clinical trial formula to elevate the country to the top of the category. “a center of excellence in clinical trials. ” Regional Center of Excellence. “
“Clinical trials are a vital component of pharmaceutical studies and development, as they offer patients features to obtain cutting-edge treatments, opportunities for fitness professionals to develop their wisdom and delight in cutting-edge studies being conducted globally, and for Philippine society to participate in the advancement of science and fitness through studies. We fully support this vision of making the Philippines a clinical trial center to advance science and fitness in the country and the region,” said the director of UP-NIH’s National Center for Clinical Trials and Translation. Benjamin P. Sablan, Jr.
Drug and vaccine testing and progression is a lengthy, risky, and complex procedure that requires significant investment and expertise. On average, researchers must identify a promising drug from 5,000 to 10,000 selected compounds. Researchers then thoroughly verify the compound to ensure its efficacy and safety, a process that can take 10 to 15 years. Most of this R&D process
“Clinical trials offer the Philippines a faster path to becoming a leader and center of excellence in the region. We can lead the ASEAN region in advancing medical and biopharmaceutical research and development, which, as we have seen, is very important for targeting the public. fitness emergencies like the COVID-19 pandemic. We are revered to collaborate with our partners in government, academia and patient organizations to realize this vision of people’s fitness and our country’s clinical and economic progress,” said PHAP President Dr. Ann S. Schulz. Diana Edralin, whose organization represents the biopharmaceutical industry in the Philippines.
In her message, the British ambassador to the Philippines, Laure Beaufils, expressed her support for the country’s aspiration to become a centre of excellence in clinical trials for healthcare, boost studies and create jobs.
“I reiterate the UK’s unwavering commitment to the Philippines to remain a trusted partner for fitness and science, especially as we recover from the COVID pandemic. Our most notable achievement in this sector over the past four years has been building nimble marriages in the dynamic landscape of fitness and science in the Philippines, rooted in a shared commitment to leave no one behind: walang iwanan. And we hope that the years ahead will allow us to build on an even more potent foundation of our marriages as a Force for Good. ” she said.
The Philippines has been conducting clinical trials for many years. In 2022, 82 clinical trials were introduced and 57 had already done so by mid-2023. Approximately 80% of those trials are global industry-sponsored clinical trials for the application and marketing authorization of new drugs. worldwide, and the Philippines participates in approximately 5% of all such global clinical trials. Southeast Asian countries bordering the Philippines, such as Malaysia, Singapore, and Thailand, have maintained a robust number of clinical trials, while Vietnam continues to grow year-on-year. -year at a CAGR of 5. 32%.
“A physically powerful innovation ecosystem serves to find and achieve breakthroughs in cancer, tuberculosis, intellectual fitness, and diabetes, among several fitness challenges. PHAP is committed to collaborating with the government and the fitnesscare network to create this environment in the country by sending recommendations. position the Philippines as a center of excellence for clinical trials across ASEAN,” said PHAP Executive Director M. Teodoro Padilla.
Among the panel of experts who took part in the forum were Dr. Mercedes Dela Viña, Adult Medicine Specialist at Healthserv Los Banos Medical Center, for the “Overview of Conducting Clinical Trials in the Philippines”; the Executive Director of the PCHRD, Dr. Jaime Montoya, for the theme “Clinical Research as a Platform for Innovation and Access: What it takes to be a Center of Excellence”; Dr. Fides María Aileen Buenafe, Head of the Pharmaceutical Division of the DOH, for “Innovation and Access”; Ms. Zohra Jane Esperal, Head of Clinical Operations and IQVIA Site Partner, for “The Economic Footprint of Clinical Research”; Dr. Pei Chieh Fong, Global Vice President Medical, AstraZeneca, for the “Value of Clinical Trial Data and Research Results for Innovations in Treatment and Diagnostics”; and Ms. Anna Ordinario, former President and Honorary Member of the PCRP, for “The State of Clinical Trials in the Philippines. “
Also on the reactor panel were Dr. Iris Tagaro of the Food and Drug Administration; Edralin, President of PHAP and Managing Director of Roche Philippines; Dr. Nancy Bermal of Unilab; Dr. Corazon Ngelangel, Asian Hospital, Dr. Sonia Bongala, Health Research Ethics Board of the Philippines, Dr. Sonia Bongala, Ph. D. Ms. Rosario Capeding, Tropical Diseases Foundation and Ms. Marimel Lamsin of the Philippine Alliance of Patient Organizations. The consultation was moderated by Dr. Melissa Bulao, PCHRD Supervising Scientific Research Specialist.
ADVT
We use cookies to give you the best experience on our website. By continuing, you agree to our use of cookies. For more information, click on this link.